HMGCR and cirrhosis of liver: Patients who received nintedanib had a higher risk of DILI from inpatient diagnosis using specific codes after adjusting for variables including sex, age group, comorbidity (nonalcoholic fatty liver disease, hepatitis B virus infection, hepatitis C virus infection, nonalcoholic steatohepatitis, alcoholic liver disease, biliary disease, liver cancer, liver cirrhosis, Epstein–Barr virus disease, and autoimmune hepatitis), and comedication (antibiotics, nonsteroidal anti-inflammatory drugs, HMG-CoA reductase inhibitor, proton pump inhibitors), with an aIRR of 3.62 (95% CI 1.11–11.78).